-+ 0.00%
-+ 0.00%
-+ 0.00%

*Immunovant: In Light of Evolving Sjögren's Disease Landscape and Recent Data in the Field, Expect It Is Unlikely That We Will Advance IMVT-1402 Further in SjD Beyond the Ongoing, Fully Enrolled Phase 2 Trial >IMVT

Dow Jones·11/09/2026 12:16:00

Please log in to view news